Johnson & Johnson $JNJ Stake Boosted by CHICAGO TRUST Co NA

Key Points

• CHICAGO TRUST Co NA increased its stake in Johnson & Johnson by 36.1% during the second quarter, now owning 24,357 shares valued at approximately $3.7 million.
• Several analysts upgraded Johnson & Johnson's stock rating, with the consensus target price rising to $181.40, and the company currently has an average rating of "Moderate Buy".
• Despite a significant sale of shares by EVP Jennifer L. Taubert, Johnson & Johnson's stock closed up 1.2%, reflecting a strong market presence with a market cap of $424.71 billion.

CHICAGO TRUST Co NA lifted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 24,357 shares of the company's stock after buying an additional 6,467 shares during the quarter. CHICAGO TRUST Co NA's holdings in Johnson & Johnson were worth $3,721,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Lantz Financial LLC raised its holdings in shares of Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after buying an additional 377 shares during the last quarter. Apexium Financial LP raised its stake in Johnson & Johnson by 10.7% during the 1st quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after acquiring an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC raised its stake in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after acquiring an additional 2,526 shares in the last quarter. Avanza Fonder AB raised its stake in Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company's stock valued at $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Johnson & Johnson by 7.0% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after purchasing an additional 4,816 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Guggenheim upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their target price for the stock from $167.00 to $206.00 in a research report on Tuesday. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research report on Thursday, July 17th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Bank of America boosted their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $181.40.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.2%

JNJ opened at $176.35 on Wednesday. The stock has a market cap of $424.71 billion, a PE ratio of 18.86, a price-to-earnings-growth ratio of 2.22 and a beta of 0.40. The stock's fifty day simple moving average is $173.56 and its 200 day simple moving average is $161.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. The business's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.